Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.

Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
ABBISKO THERAPEUTICS PRESENTS LONGER-TERM EFFICACY AND SAFETY OUTCOMES FROM PHASE III MANEUVER TRIAL OF PIMICOTINIB AT ESMO 2025

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced that longer-term efficacy and safety outcomes from the global phase III MANEUVER trial of pimicotinib (ABSK021) in patients with tenosynovial giant cell tumour ("**TGCT**") were orally presented at the European Society for Medical Oncology 2025 ("**ESMO 2025**"). This longer-term analysis demonstrated that tumour responses to pimicotinib, as assessed by objective response rate ("**ORR**") by blinded independent review committee ("**BIRC**") per RECIST v1.1 and tumor volume score ("**TVS**") continued to deepen and improve with time and were durable, with ongoing clinically meaningful improvements in clinical outcome assessments ("**COAs**"; including range of motion, stiffness, pain, and physical function), and a safety profile consistent with previous analyses, supporting the feasibility of longer-term treatment.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK021 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, October 17, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

Abbisko Therapeutics Presents Longer-Term Efficacy and Safety Outcomes from Phase III MANEUVER Trial of Pimicotinib at ESMO 2025

On 17 October 2025, Shanghai, Abbisko Therapeutics Co. Ltd. ("**Abbisko Therapeutics**") announced that longer-term efficacy and safety outcomes from the global phase III MANEUVER trial of pimicotinib (ABSK021) in patients with tenosynovial giant cell tumour ("**TGCT**") were orally presented at the European Society for Medical Oncology 2025 ("**ESMO 2025**"). This longer-term analysis demonstrated that tumour responses to pimicotinib, as assessed by objective response rate ("**ORR**") by blinded independent review committee ("**BIRC**") per RECIST v1.1 and tumor volume score ("**TVS**") continued to deepen and improve with time and were durable, with ongoing clinically meaningful improvements in clinical outcome assessments ("**COAs**"; including range of motion, stiffness, pain, and physical function), and a safety profile consistent with previous analyses, supporting the feasibility of longer-term treatment.

TGCT is a rare mesenchymal and locally aggressive tumor primarily affecting joints, tendon sheaths, and bursae with potentially devastating morbidity. TGCT is driven by overexpression of colony-stimulating factor-1 ("**CSF-1**") in neoplastic synovial cells that leads to accumulation of colony-stimulating factor-1 receptor ("**CSF-1R**") – expressing inflammatory cells in the tumor.

Pimicotinib is a novel, oral, highly selective, and potent small-molecule CSF-1R inhibitor independently developed by Abbisko Therapeutics. Its global phase III MANEUVER trial consists of three parts and is designed to evaluate the efficacy and safety of pimicotinib in patients with TGCT. The results from Part 1 of MANEUVER trial, presented at the 2025 American Society of Clinical Oncology ("**ASCO**") Annual Meeting, showed that pimicotinib provided significant efficacy benefits for patients. At week 25, the ORR assessed by BIRC per RECIST v1.1 was 54% in the pimicotinib treatment group, compared to only 3.2% in the placebo control group.

At the ESMO 2025, Prof. Xiaohui Niu from Beijing Jishuitan Hospital, leading principal investigator ("**PI**") of MANEUVER trial, reported the longer-term efficacy and safety outcomes. With a median follow-up of 14.3 months, the ORR assessed by BIRC per RECIST v1.1 in patients randomized to pimicotinib in Part 1 increased to 76.2% (95% CI: 63.8, 86.0), with the median duration of response ("**mDOR**") not yet reached (range: 0.03-19.81 months). At the end of Part 2 (week 49), the COAs showed ongoing improvements with a good safety profile. Up to Week 73, pimicotinib showed a mean change from baseline of 23.9% in relative range of motion. Patients who were randomized to placebo in Part 1 and then switched to pimicotinib in Part 2 also achieved benefit, with an ORR of 64.5% by both BICR per RECIST v1.1 and TVS, as well as improvements in COAs.

As accumulating data further validate the efficacy, safety, and tolerability of pimicotinib in the longer-term management of TGCT, its potential to become a best-in-class therapy and its commercial value are poised for progressive realization.

About Pimicotinib

Pimicotinib is a novel, oral, highly selective, and potent small-molecule CSF-1R inhibitor independently developed by Abbisko Therapeutics. Positive top-line results from the global Phase III MANEUVER study of pimicotinib for the treatment of TGCT were announced in November 2024. Currently, pimicotinib has been included in the priority review process by the Center for Drug Evaluation ("**CDE**") of the National Medical Products Administration ("**NMPA**") in China for the treatment of adult TGCT patients requiring systemic therapy. Pimicotinib also has been granted breakthrough therapy designation ("**BTD**") by the NMPA. In December 2023, Abbisko Therapeutics entered into an agreement with Merck KGaA, Darmstadt, Germany, pertaining to the commercial rights to pimicotinib, pursuant to which Merck KGaA, Darmstadt, Germany, is responsible for the commercialization of pimicotinib globally.

Outside of China, pimicotinib has been granted BTD by the US Food and Drug Administration ("**FDA**") and PRIME Designation by the European Medicines Agency ("**EMA**").

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.